ALK and small cell lung carcinoma: Choi et al. reported that the addition of WNT3a or R-spondin1, as well as ALK inhibitor and BMP inhibitor, is a prerequisite for the long-term expansion of small-cell lung cancer (SCLC) tumor organoids [95].